Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 307.

https://doi.org/10.1182/blood.V130.Suppl_1.307.307

Published: 2017

Journal Articles

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Guido Ghilardi, MD, Thomas Pabst, MD, Barbara Jeker, MD, Rouven Müller, MD, Anne Cairoli, MD, Antonia Mueller, MD, Mario Bargetzi, MD, Felicitas Hitz, MD, Helen Baldomero, Dominik Heim, MD, Davide Rossi, MD PhD, Michele Ghielmini, MD, Erika Lerch, MD, Urs Schanz, MD, Jakob R. Passweg, MDMS, Georg Stussi, MD, Martina Kleber, MD, Bernhard Gerber

Blood (2017) 130 (Supplement 1): 3297.

https://doi.org/10.1182/blood.V130.Suppl_1.3297.3297

Published: 2017

Journal Articles

Plasma Cell Disease Genotyping with the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 327.

https://doi.org/10.1182/blood.V130.Suppl_1.327.327

Published: 2017

Journal Articles

Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Liat Vidal, MD MSc, Anat Gafter-Gvili, MD, Martin H. Dreyling, Michael Unterhalt, PhD, Pia Raanani, MD, Michele Ghielmini, MD professor, Ronit Gurion

Blood (2016) 128 (22): 1802.

https://doi.org/10.1182/blood.V128.22.1802.1802

Published: 2016

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Rituximab Maintenance (MR) for Patients with Mantle Cell Lymphoma (MCL) – a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Liat Vidal, MDMSc, Anat Gafter-Gvili, MD, Martin Dreyling, Michele Ghielmini, MD, Michael Unterhalt, MD, Pia Raanani, MD, Ofer Shpilberg, MD, Ron Ram, MD, Ronit Gurion, MD

Blood (2014) 124 (21): 4466.

https://doi.org/10.1182/blood.V124.21.4466.4466

Published: 2014

Journal Articles

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

Isabelle Fleury, MD, Sylvie Chevret, MD PhD, Michael Pfreundschuh, Gilles Salles, MDPhD, Bertrand Coiffier, MD PhD, Marinus H.J. van Oers, Christian Gisselbrecht, MDPhD, Emanuele Zucca, MD, Michael Herold, MDPhD, Michele Ghielmini, MD, Catherine Thieblemont, MDPhD

Blood (2014) 124 (21): 1659.

https://doi.org/10.1182/blood.V124.21.1659.1659

Published: 2014

Journal Articles

The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure

Stephen Paul Robinson, MBBS, MRCP, FRCPath, PhD, Paolo Corradini, Peter Dreger, MD, Dolores Caballero, MD, PhD, Christian H Geisler, Michele Ghielmini, MD, Steven Le Gouill, MD, PhD, Eva Kimby, MD, Simon Rule, MD, Umberto Vitolo, Martin Dreyling, O. Hermine, MD, PhD

Blood (2013) 122 (21): 3405.

https://doi.org/10.1182/blood.V122.21.3405.3405

Published: 2013

Journal Articles

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Giovanni Martinelli, Felicitas Hitz, Walter Mingrone, Thomas Pabst, MD, Lidija Cevreska, Auro del Giglio, MD, Anna Vanazzi, Daniele Laszlo, Johann Raats, Daniel Rauch, Daniel A. Vorobiof, Andreas Lohri, MD, Emanuele Zucca, MD, Christine Biaggi Rudolf, Stephanie Rondeau, Corinne Rusterholz, Michele Ghielmini, MD

Blood (2013) 122 (21): 508.

https://doi.org/10.1182/blood.V122.21.508.508

Published: 2013

Journal Articles

Histologic Transformation in Marginal Zone Lymphomas

Silvia Franceschetti, MD, Annarita Conconi, MD, Kathrin Aprile Von Hohenstaufen, MD, Gloria Margiotta Casaluci, MD, Anastasios Stathis, MD, Alden Moccia, MD, Michele Ghielmini, MD, Francesco Bertoni, MD, Gianluca Gaidano, MD, PhD, Franco Cavalli, MD, Emanuele Zucca, MD

Blood (2012) 120 (21): 1571.

https://doi.org/10.1182/blood.V120.21.1571.1571

Published: 2012

Journal Articles

Meta Analysis of Grade 3 and/or 4 Toxicities in Follicular (FL) and Mantle Cell (MCL) Non-Hodgkin Lymphoma (NHL) Patients Receiving Maintenance Rituximab (MR): Impact of Schedule, Histology, and Induction Regimen

Chadi Nabhan, MD, FACP, Dana Villines, M.A., Brian C-H Chiu, Ph.D., Nicholas J. Ollberding, Ph. D., Tina V. Valdez, D. O., Michele Ghielmini, MD, Shu-Fang H. Schmitz, Ph. D., Sonali M. Smith, MD

Blood (2012) 120 (21): 3654.

https://doi.org/10.1182/blood.V120.21.3654.3654

Published: 2012

Journal Articles

Expression of Inhibitory Fc Receptor (FcγRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).

Chern Siang Lee, MB BS, Margaret Ashton-Key, MD FRCPath, Sergio Cogliatti, Susanne Crowe, Mark S Cragg, PhD, Shu-Fang H Schmitz, Michele Ghielmini, MD, Peter Johnson

Blood (2012) 120 (21): 2747.

https://doi.org/10.1182/blood.V120.21.2747.2747

Published: 2012

Journal Articles

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

Chiara Lobetti-Bodoni, MD, Paola MV Rancoita, PhD, Silvia Montoto, MD, Armando Lopez-Guillermo, MD, Annarita Conconi, MD, Rita Coutinho, MD, Janet Matthews, Silvia Franceschetti, MD, Francesco Bertoni, MD, Franco Cavalli, MD, Michele Ghielmini, MD, Andrew Lister, MD, Emili Montserrat, MD, Emanuele Zucca, MD

Blood (2011) 118 (21): 1593.

https://doi.org/10.1182/blood.V118.21.1593.1593

Published: 2011

Journal Articles

Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers

Annarita Conconi, MD, Silvia Franceschetti, MD, Chiara Lobetti-Bodoni, MD, Anastasios Stathis, MD, Riccardo Bruna, MD, Paola Riccomagno, MD, Francesco Bertoni, MD, Michele Ghielmini, MD, Franco Cavalli, MD, Gianluca Gaidano, Emanuele Zucca, MD

Blood (2011) 118 (21): 2660.

https://doi.org/10.1182/blood.V118.21.2660.2660

Published: 2011

Journal Articles

Meta Analysis of Grade 3 and/or 4 Toxicities in Low-Grade Non-Hodgkin Lymphoma (LG-NHL) Patients Receiving Maintenance Rituximab (MR) Therapy: Impact of Schedule on Toxicity

Chadi Nabhan, MD, FACP, Dana Villines, M.A., Tina V. Valdez, D. O., Michele Ghielmini, MD, Shu-Fang Hsu Schmitz, Sonali M. Smith, MD

Blood (2011) 118 (21): 2704.

https://doi.org/10.1182/blood.V118.21.2704.2704

Published: 2011

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Simona Bassi, Felicitas Hitz, Walter Mingrone, Thomas Pabst, Lidija Cevreska, MD, PhD, Auro del Giglio, MD, Daniel A. Vorobiof, Mathew Simcock, Michele Ghielmini, MD

Blood (2010) 116 (21): 1802.

https://doi.org/10.1182/blood.V116.21.1802.1802

Published: 2010

Journal Articles

Rituximab maintenance for the Treatment of patients with Follicular Lymphoma: Systematic Review and Meta-Analysis of Randomized Trials - 2010 Update.

Liat Vidal, Anat Gafter-Gvili, MD, Gilles Salles, Martin H. Dreyling, MD, Michele Ghielmini, MD, Shu-Fang Hsu Schmitz, Ruth Pettengell, FRACP, PhD, Mathias Witzens-Harig, Ofer Shpilberg, MD, MPH

Blood (2010) 116 (21): 1798.

https://doi.org/10.1182/blood.V116.21.1798.1798

Published: 2010

Journal Articles

Meta Analysis: Rituximab as Maintenance Therapy for Patients with Follicular Lymphoma.

Liat Vidal, MD, Anat Gafter-Gvili, MD, Martin Dreyling, MD, PhD, Michele Ghielmini, MD, Shu Fang Hsu-Schmitz, PhD, Leibovici Leonard, MD, Amos Cohen, MD, Ofer Shpilberg, MD, MPH

Blood (2007) 110 (11): 3408.

https://doi.org/10.1182/blood.V110.11.3408.3408

Published: 2007

Journal Articles

A Phase I–II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab, with a Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function.

Marco Siano, M.D., Erika Lerch, M.D., Emanuele Zucca, M.D., Oreste Mora, M.D., Cristiana Sessa, M.D., Michele Ghielmini, MD

Blood (2007) 110 (11): 3411.

https://doi.org/10.1182/blood.V110.11.3411.3411

Published: 2007

NARROW

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Plasma Cell Disease Genotyping with the Liquid Biopsy

Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Rituximab Maintenance (MR) for Patients with Mantle Cell Lymphoma (MCL) – a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Histologic Transformation in Marginal Zone Lymphomas

Meta Analysis of Grade 3 and/or 4 Toxicities in Follicular (FL) and Mantle Cell (MCL) Non-Hodgkin Lymphoma (NHL) Patients Receiving Maintenance Rituximab (MR): Impact of Schedule, Histology, and Induction Regimen

Expression of Inhibitory Fc Receptor (FcγRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers

Meta Analysis of Grade 3 and/or 4 Toxicities in Low-Grade Non-Hodgkin Lymphoma (LG-NHL) Patients Receiving Maintenance Rituximab (MR) Therapy: Impact of Schedule on Toxicity

Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03

Rituximab maintenance for the Treatment of patients with Follicular Lymphoma: Systematic Review and Meta-Analysis of Randomized Trials - 2010 Update.

Meta Analysis: Rituximab as Maintenance Therapy for Patients with Follicular Lymphoma.

A Phase I–II Study To Determine the Maximum Tolerated Infusion-Rate of Rituximab, with a Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only